Cambridge NeuroScience
Executive Summary
Files for orphan drug designation of pramiracetam as an adjunct to electroshock therapy, start-up firm announces July 2. CNS acquired the drug from Warner-Lambert as part of strategy to help fund R&D by acquiring near-term or already marketed products in niche neuropsychiatric markets ("The Pink Sheet" May 27, T&G-14). The firm estimates more than 100,000 courses of electroshock therapy are given each year in the U.S. Pramiracetam Phase III trials are slated to begin in the next 12 months.